Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1050 of 1863 entries
View as:

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Phase: N/A Priority: Normal
NCT ID: NCT00107289 Org: User:
Start: 05/31/06 End: 05/31/26 Due: 05/31/27

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00130780 Org: User:
Start: 08/31/05 End: 10/31/12 Due: 10/31/13

Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations

Phase: N/A Priority: Normal
NCT ID: NCT01482923 Org: User:
Start: 11/22/11 End: 10/21/19 Due: 10/21/20

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03245541 Org: User:
Start: 08/14/20 End: 09/30/25 Due: 09/30/26

Development of a Clinical Trial Specific Question Prompt List

Phase: N/A Priority: Normal
NCT ID: NCT00662324 Org: User:
Start: 04/30/08 End: 05/31/13 Due: 05/31/14

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Phase: N/A Priority: Normal
NCT ID: NCT00591851 Org: User:
Start: 12/31/04 End: 06/30/08 Due: 06/30/09

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance

Phase: N/A Priority: Normal
NCT ID: NCT00581646 Org: User:
Start: 09/30/06 End: 06/30/15 Due: 06/30/16

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01474564 Org: User:
Start: 11/30/11 End: 10/31/19 Due: 10/31/20

Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04210128 Org: User:
Start: 12/20/19 End: 10/31/23 Due: 10/31/24

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00805129 Org: User:
Start: 12/05/08 End: 12/15/21 Due: 12/15/22

Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity

Phase: N/A Priority: Normal
NCT ID: NCT00582413 Org: User:
Start: 12/31/04 End: 10/31/14 Due: 10/31/15

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02498912 Org: User:
Start: 08/31/15 End: 08/31/25 Due: 08/31/26

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03245892 Org: User:
Start: 08/04/17 End: 08/31/25 Due: 08/31/26

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03085173 Org: User:
Start: 03/15/17 End: 03/31/26 Due: 03/31/27

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00027638 Org: User:
Start: 03/31/01 End: 12/31/03 Due: 12/31/04

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01913639 Org: User:
Start: 07/31/13 End: 06/30/19 Due: 06/30/20

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02228525 Org: User:
Start: 08/27/14 End: 04/06/21 Due: 04/06/22

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

Phase: N/A Priority: Normal
NCT ID: NCT01664936 Org: User:
Start: 08/08/12 End: 04/03/18 Due: 04/03/19

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01404949 Org: User:
Start: 07/31/11 End: 02/01/21 Due: 02/01/22

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003037 Org: User:
Start: 04/30/97 End: 03/31/02 Due: 03/31/03

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Phase: N/A Priority: Normal
NCT ID: NCT02358018 Org: User:
Start: - End: - Due: -

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01183416 Org: User:
Start: 08/31/10 End: 10/31/18 Due: 10/31/19

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01542021 Org: User:
Start: 02/24/12 End: 09/30/24 Due: 09/30/25

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004928 Org: User:
Start: 10/31/99 End: 10/31/04 Due: 10/31/05

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Phase: N/A Priority: Normal
NCT ID: NCT01300429 Org: User:
Start: 02/08/11 End: 01/05/21 Due: 01/05/22